Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Randox Teoranta currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units. This means that each of the 2 pending office actions is being handled by a different individual in a different specialized division of the patent office. With 2 distinct art units involved, the company must navigate the specific examination guidelines and technical requirements of two separate areas within the biotechnology sector.
The busiest examiner for this portfolio is HAQ, SHAFIQUL, who is overseeing 1 busiest examiner pending office action. This represents a portion of the total 2 pending office actions. Because the 2 pending office actions are split between 2 distinct examiners, the company's success depends on independent reviews. Practitioners should be prepared for different interpretations of biological claims, as the 1 busiest examiner pending office action under HAQ, SHAFIQUL is isolated from the other active matter. This distribution across 2 distinct art units suggests that the company's pharmaceutical innovations span multiple technical classifications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §103 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAQ, SHAFIQUL | 1 | 64.8% | +55.2% |
| SAOUD, CHRISTINE J | 1 | 57.9% | +37.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283652 | METHOD OF DETERMINING PROGNOSIS OF CHRONIC KIDNEY DISEASE | SAOUD, CHRISTINE J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284783 | DETECTION ASSAY | HAQ, SHAFIQUL | — |
| 18283652 | METHOD OF DETERMINING PROGNOSIS OF CHRONIC KIDNEY DISEASE | SAOUD, CHRISTINE J | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18284783 | DETECTION ASSAY | HAQ, SHAFIQUL | 1678 | §103 | Final Rejection | — | Pending | Sep 28, 2023 |
| 18283652 | METHOD OF DETERMINING PROGNOSIS OF CHRONIC KIDNEY DISEASE | SAOUD, CHRISTINE J | 1645 | §101§102§112 | Non-Final OA | — | Pending | Sep 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRandox Teoranta has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Shafiqul Haq has the most, with 1 of Randox Teoranta's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
